5 cases of liver metastases of differentiated thyroid cancer (DTC) were given follow-up after 131I therapy. The results were evaluated with clinical appearence

blood examination

radionuclide imaging and survival analysis. The results showed that (1) all cases had survived for 2-9 years in follow-up period; (2) liver metastastic lesion was disappeared after taking 44.77 GBq 131I

as demonstrated by 131I scan and ultrasonic imaging; (3) the sequences and doses of 131I for normal ablation were significantly decreased with total thyroidectomy than with partial-thyroidectomy(P<0.05); (4) the sequences and doses of 131I for normal ablation were significantly decreased with 3.7 GBq initial 131I doses than with <3.7GBq (PO.01). The treatment of 131I with liver metastases from DTC may improve clinical symptoms

raise life quality

reduce lesion size

and prolong life survival.